JP2018534287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534287A5 JP2018534287A5 JP2018519450A JP2018519450A JP2018534287A5 JP 2018534287 A5 JP2018534287 A5 JP 2018534287A5 JP 2018519450 A JP2018519450 A JP 2018519450A JP 2018519450 A JP2018519450 A JP 2018519450A JP 2018534287 A5 JP2018534287 A5 JP 2018534287A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- channel
- tamapin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001026230 Homo sapiens Small conductance calcium-activated potassium channel protein 2 Proteins 0.000 claims description 30
- 101001049895 Hottentotta tamulus Potassium channel toxin alpha-KTx 5.4 Proteins 0.000 claims description 25
- 108091006146 Channels Proteins 0.000 claims description 24
- 208000012902 Nervous system disease Diseases 0.000 claims description 19
- 210000000653 nervous system Anatomy 0.000 claims description 17
- 102100037446 Small conductance calcium-activated potassium channel protein 2 Human genes 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 210000003754 fetus Anatomy 0.000 claims description 10
- 208000025966 Neurological disease Diseases 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 101001026236 Homo sapiens Intermediate conductance calcium-activated potassium channel protein 4 Proteins 0.000 claims description 8
- 101000974731 Homo sapiens Small conductance calcium-activated potassium channel protein 1 Proteins 0.000 claims description 8
- 101001026232 Homo sapiens Small conductance calcium-activated potassium channel protein 3 Proteins 0.000 claims description 8
- 102100022747 Small conductance calcium-activated potassium channel protein 1 Human genes 0.000 claims description 8
- 102100037442 Small conductance calcium-activated potassium channel protein 3 Human genes 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 201000003723 learning disability Diseases 0.000 claims description 8
- 208000020358 Learning disease Diseases 0.000 claims description 6
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 101710126338 Apamin Proteins 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010016845 Foetal alcohol syndrome Diseases 0.000 claims description 4
- 102100037441 Intermediate conductance calcium-activated potassium channel protein 4 Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000007794 fetal alcohol syndrome Diseases 0.000 claims description 4
- RWDGJWWPTGBMRD-HOSVXTCQSA-N lei-dab7 Chemical compound C([C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]1C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(N)=O)=O)NC(=O)[C@H](C)N)C1=CC=CC=C1 RWDGJWWPTGBMRD-HOSVXTCQSA-N 0.000 claims description 4
- YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000009575 Angelman syndrome Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 201000006347 Intellectual Disability Diseases 0.000 claims description 2
- 208000036626 Mental retardation Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 210000000133 brain stem Anatomy 0.000 claims description 2
- 239000013043 chemical agent Substances 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 239000004480 active ingredient Substances 0.000 claims 11
- 239000003607 modifier Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003061 neural cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240561P | 2015-10-13 | 2015-10-13 | |
| US62/240,561 | 2015-10-13 | ||
| PCT/US2016/056835 WO2017066444A1 (en) | 2015-10-13 | 2016-10-13 | Treatment of learning disabilities and other neurological disorders with sk channel inhibitor(s) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534287A JP2018534287A (ja) | 2018-11-22 |
| JP2018534287A5 true JP2018534287A5 (enExample) | 2019-12-19 |
| JP6987749B2 JP6987749B2 (ja) | 2022-01-05 |
Family
ID=58518316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519450A Active JP6987749B2 (ja) | 2015-10-13 | 2016-10-13 | Ｓｋチャネル阻害剤による学習障害および他の神経障害の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10555989B2 (enExample) |
| EP (1) | EP3362081B1 (enExample) |
| JP (1) | JP6987749B2 (enExample) |
| WO (1) | WO2017066444A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113422142B (zh) * | 2021-05-18 | 2022-06-24 | 金华职业技术学院 | 一种新能源汽车电池模组高效散热装置 |
| GB202313820D0 (en) * | 2023-09-11 | 2023-10-25 | Imperial College Innovations Ltd | Peptide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2918282B1 (fr) | 2007-07-02 | 2009-10-02 | Assistance Publique Hopitaux P | Medicament pour le traitement de la maladie de parkinson |
| WO2010015037A1 (en) * | 2008-08-08 | 2010-02-11 | Howard Florey Institute | Therapeutic methods and compositions |
| US20140356343A1 (en) * | 2011-12-05 | 2014-12-04 | Key Neurosciences Sas | Composition for treating parkinson's disease |
-
2016
- 2016-10-13 WO PCT/US2016/056835 patent/WO2017066444A1/en not_active Ceased
- 2016-10-13 EP EP16856191.8A patent/EP3362081B1/en active Active
- 2016-10-13 JP JP2018519450A patent/JP6987749B2/ja active Active
- 2016-10-13 US US15/767,361 patent/US10555989B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10758497B2 (en) | Treatment of fragile x syndrome with cannabidiol | |
| EP2991637B1 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| Harel et al. | Successful treatment of rheumatic chorea with carbamazepine | |
| JP2009538853A5 (enExample) | ||
| KR20200055067A (ko) | 성인의 초점성 뇌전증의 치료를 위한 합성 경피성 칸나비디올 | |
| KR20150047573A (ko) | 최면 진정제의 투여 방법 | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2018534287A5 (enExample) | ||
| JP2023532880A (ja) | カンナビジオールによる脆弱ｘ症候群の処置 | |
| EP3490550A1 (en) | A2-73 as a therapeutic for insomnia, anxiety, and agitation | |
| JP2018530612A5 (enExample) | ||
| CN103002893A (zh) | 神经障碍性疼痛的治疗药或预防药 | |
| EP3939581B1 (en) | Estrogen receptor ligands, compositions and methods related thereto | |
| JP6550656B2 (ja) | 炎症性皮膚疾患の予防または治療用製剤 | |
| WO2018151285A1 (ja) | 掻痒性皮膚疾患の予防又は治療薬 | |
| KR960006068B1 (ko) | 이미다벤조디아제핀을 함유하는 공포상태의 예방 및 중지용 약제 | |
| US12502371B2 (en) | Drug for treating and preventing dementia | |
| KR101695680B1 (ko) | 이피다크린을 포함하는 약제학적 조성물과 성기능 장애 및 다른 형태의 성활동의 장애의 치료를 위한 그의 용도 | |
| JP2024030188A (ja) | 女性のうつ症状を改善するための医薬組成物 | |
| US10438128B2 (en) | Treatment of autoimmune and inflammatory diseases with the arsenic compounds AS2O3 and/or AS2O5 administered locally | |
| Ewing | The First Phase of Alcoholic Rehabilitation. Report of a Controlled Study with Benactyzine, Paraldehyde and Pyridoxine | |
| JP2017088584A (ja) | 医薬組成物 | |
| Azcona et al. | Effects of the muscarinic agonist RS 86 in healthy volunteers | |
| Al Abadey | Investigating the effects of Kappa opioid receptor agonists on remyelination in a preclinical model of multiple sclerosis |